Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Kidney-targeted baicalin-lysozyme conjugate ameliorates renal fibrosis in rats with diabetic nephropathy induced by streptozotocin

Fig. 2

BAI-LZM alleviates renal impairment in rats with DN. Renal tissue sections from each rat were stained with (a) hematoxylin and eosin, (b) periodic acid-Schiff or (c) Masson’s trichrome stain. Representative images of a rat per group are displayed (magnification, × 400). Blue arrow, mesangial matrix expansion; red arrow, glomerular basement membrane thickening. Con, saline; DN, 65 mg/kg STZ; DN/B, 65 mg/kg STZ + 160 mg/kg/day BAI; DN/B + L, 65 mg/kg STZ + 160 mg/kg/day BAI-LZM. The results are representative of 3 independent experiments. Data are presented as the mean ± standard deviation. *P < 0.05, **P < 0.01 between the values in DN, DN/B and DN/B + L rats vs. the baseline levels (Con), as calculated by Student’s t test. #P < 0.05, ##P < 0.01 between the DN and BAI/BAI-LZM treatment groups, as calculated by one-way analysis of variance. $P < 0.05, $$P < 0.01 between the BAI and BAI-LZM treatment groups, as calculated by one-way analysis of variance. P-values were calibrated using the Bonferroni correction. BAI-LZM, baicalin-lysozyme; DN, diabetic nephropathy; STZ, streptozotocin; Con, control

Back to article page